IS5560A - Efnablanda með tafða losun, aðferð til að framleiða hana og notkun hennar - Google Patents

Efnablanda með tafða losun, aðferð til að framleiða hana og notkun hennar

Info

Publication number
IS5560A
IS5560A IS5560A IS5560A IS5560A IS 5560 A IS5560 A IS 5560A IS 5560 A IS5560 A IS 5560A IS 5560 A IS5560 A IS 5560A IS 5560 A IS5560 A IS 5560A
Authority
IS
Iceland
Prior art keywords
preparation
delayed release
release preparation
delayed
release
Prior art date
Application number
IS5560A
Other languages
English (en)
Inventor
Saikawa Akira
Igari Yasutaka
Hata Yoshio
Yamamoto Kazumichio
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of IS5560A publication Critical patent/IS5560A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
IS5560A 1998-01-16 2000-07-11 Efnablanda með tafða losun, aðferð til að framleiða hana og notkun hennar IS5560A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP641298 1998-01-16
PCT/JP1999/000086 WO1999036099A1 (fr) 1998-01-16 1999-01-13 Compositions a liberation controlee, leur procede de fabrication et leur utilisation

Publications (1)

Publication Number Publication Date
IS5560A true IS5560A (is) 2000-07-11

Family

ID=11637664

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5560A IS5560A (is) 1998-01-16 2000-07-11 Efnablanda með tafða losun, aðferð til að framleiða hana og notkun hennar

Country Status (19)

Country Link
US (2) US6740634B1 (is)
EP (1) EP1048301A4 (is)
KR (1) KR100577877B1 (is)
CN (1) CN1199686C (is)
AU (1) AU758596B2 (is)
BR (1) BR9906903A (is)
CA (1) CA2316273A1 (is)
HR (1) HRP20000471A2 (is)
HU (1) HUP0100221A3 (is)
IL (1) IL136951A0 (is)
IS (1) IS5560A (is)
NO (1) NO20003530L (is)
NZ (1) NZ505651A (is)
OA (1) OA11446A (is)
PL (1) PL341733A1 (is)
RU (1) RU2230550C2 (is)
SK (1) SK10272000A3 (is)
TR (1) TR200002059T2 (is)
WO (1) WO1999036099A1 (is)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
WO2000035990A1 (fr) 1998-12-15 2000-06-22 Takeda Chemical Industries, Ltd. Procede de production d'un polymere
WO2001005380A1 (fr) 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
CA2412899C (en) 2000-07-05 2010-11-09 Takeda Chemical Industries, Ltd. Medicinal preparations for treating sex hormone-dependent diseases
PT1693054T (pt) 2000-08-07 2016-07-07 Takeda Pharmaceuticals Co Polímero de ácido láctico e processo para a sua produção
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
AU2002221139A1 (en) * 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
EP1374855A1 (en) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medicinal solutions
US20040235748A1 (en) * 2001-04-25 2004-11-25 Yasutaka Igari Agents for preventing postoperative recurrence of premenopausal breast cancer
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
BRPI0213226B1 (pt) 2001-10-10 2016-03-01 Pf Medicament processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
CN101444476B (zh) * 2001-12-26 2011-11-30 武田药品工业株式会社 新微球和其生产方法
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
EP1532985B1 (en) * 2002-06-25 2016-10-12 Takeda Pharmaceutical Company Limited Process for producing a sustained-release composition
WO2004029129A1 (ja) * 2002-09-24 2004-04-08 Asahi Kasei Chemicals Corporation グリコール酸共重合体及びその製造方法
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
BRPI0412211A (pt) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
JP2007527409A (ja) * 2003-10-09 2007-09-27 インバーセオン、インコーポレイテッド β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
EP1716847B1 (en) * 2005-04-28 2008-01-02 Nipro Corporation Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
US20070027107A1 (en) * 2005-07-29 2007-02-01 Curt Hendrix Compositions and methods for treating estrogen-dependent diseases and conditions
EP1981525B1 (en) * 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
EP1996162A2 (en) * 2006-03-13 2008-12-03 Encysive Pharmaceuticals, Inc Methods and compositions for treatment of diastolic heart failure
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
PL2383271T3 (pl) * 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminochinolony jako inhibitory GSK-3
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
AU2007297597B2 (en) 2006-09-21 2013-02-21 Kyorin Pharmaceuticals Co., Ltd. Serine hydrolase inhibitors
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
MY148370A (en) * 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
AU2008299903B2 (en) * 2007-09-11 2013-08-29 Kyorin Pharmaceutical Co., Ltd Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
MY159327A (en) * 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
BRPI1008974A2 (pt) 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
JP2014503707A (ja) * 2010-12-15 2014-02-13 スリーエム イノベイティブ プロパティズ カンパニー 分解性繊維
JP6527305B2 (ja) 2011-01-10 2019-06-05 インヴィオン， インコーポレイテッド 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
AR082266A1 (es) * 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
CN103827113A (zh) 2011-06-23 2014-05-28 Map药物公司 新型氟麦角碱类似物
WO2013056070A2 (en) 2011-10-14 2013-04-18 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
AR107320A1 (es) 2016-01-08 2018-04-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
WO2017120422A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US11124839B2 (en) 2016-11-03 2021-09-21 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3432883B1 (en) 2017-02-21 2021-07-28 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
BR112020002591A2 (pt) 2017-08-07 2020-07-28 Kura Oncology, Inc. método para o tratamento de câncer
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3873469A2 (en) 2018-11-01 2021-09-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3897638A1 (en) 2018-12-21 2021-10-27 Kura Oncology, Inc. Therapies for squamous cell carcinomas
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
JP2022527495A (ja) 2019-03-29 2022-06-02 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021055376A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
AU2022232625A1 (en) 2021-03-10 2023-09-28 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
CA3234276A1 (en) 2021-11-30 2023-06-08 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
US20230416741A1 (en) 2022-05-05 2023-12-28 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049640A (en) * 1975-12-12 1977-09-20 American Cyanamid Company Substituted bisnaphthylazo diphenyl ureido complement inhibitors
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
JPH07115233B2 (ja) * 1990-08-10 1995-12-13 株式会社ヨシツカ精機 粉末成形プレス
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
WO1996022786A1 (en) 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5635765A (en) * 1996-02-26 1997-06-03 Cypress Semiconductor Corporation Multi-layer gate structure
DE69717263T2 (de) 1996-03-28 2003-07-24 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung und deren herstellung
GB9611194D0 (en) * 1996-05-29 1996-07-31 Smithkline Beecham Plc Container
WO1998020836A2 (en) * 1996-11-15 1998-05-22 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
WO2001005380A1 (fr) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla

Also Published As

Publication number Publication date
RU2230550C2 (ru) 2004-06-20
CA2316273A1 (en) 1999-07-22
CN1199686C (zh) 2005-05-04
SK10272000A3 (sk) 2001-01-18
KR20010033949A (ko) 2001-04-25
NO20003530D0 (no) 2000-07-07
BR9906903A (pt) 2000-12-12
WO1999036099A8 (fr) 1999-11-18
CN1288387A (zh) 2001-03-21
AU1889799A (en) 1999-08-02
EP1048301A1 (en) 2000-11-02
US20050025826A1 (en) 2005-02-03
HUP0100221A2 (hu) 2001-06-28
EP1048301A4 (en) 2005-03-09
NO20003530L (no) 2000-09-14
US7388032B2 (en) 2008-06-17
IL136951A0 (en) 2001-06-14
HRP20000471A2 (en) 2000-12-31
US6740634B1 (en) 2004-05-25
TR200002059T2 (tr) 2001-01-22
OA11446A (en) 2004-04-30
AU758596B2 (en) 2003-03-27
WO1999036099A1 (fr) 1999-07-22
KR100577877B1 (ko) 2006-05-09
PL341733A1 (en) 2001-05-07
HUP0100221A3 (en) 2002-11-28
NZ505651A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
IS5560A (is) Efnablanda með tafða losun, aðferð til að framleiða hana og notkun hennar
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO995063L (no) Preparat med forsinket frigjöring og fremgangsmåter for deres fremstilling
DK0909327T3 (da) Erythromyciner og fremgangsmåder til deres fremstilling
DK0789568T3 (da) Antineoplastiske kakaoekstrakter, fremgangsmåder til fremstilling og anvendelse
GB2383937B (en) Seasoning system and method
NO20021736D0 (no) Nytt preparat og fremgangsmåte for stabilisering av det
PT1181397E (pt) Electrocatalisador de rodio e metodo de preparacao
NO995090L (no) Kilesystem og utløsningsmetoder
NO20032332D0 (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
DK1949936T3 (da) Sammensætning til kontrolleret frigivelse og fremgangsmåde til fremstilling deraf
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO985307L (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvende
NO20006059L (no) Sammensatt element og fremgangsmåte for anvendelse
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
DK1061955T3 (da) Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
PL342453A1 (en) Biphenylsulphonylcyanamides, method of obtaining them and their application as drugs
NO20000290D0 (no) Isolasjonssystem, fremgangsmåte for isolering og anvendelse av isolasjonssystem
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
DK1093361T3 (da) Steroidholdigt plaster, fremgangsmåde til dets fremstilling og anvendelse heraf
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
NO970768D0 (no) Alkylert polyallylamin og fremgangsmåte for fremstilling av dette
DK1259523T3 (da) Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf